Pathological complete response

Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F et al (2011) Fimctional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8 11... [Pg.214]

Studies have found that the patients who respond to neoadjuvant chemotherapy have prolonged survival over nonresponders (median 20 vs 6.2 mo) (28). The pathologic complete response rates in studies of neoadjuvant chemotherapy alone have been a dismal 10%. More recent studies have involved the addition of neoadjuvant radiation to chemotherapy to improve on these results. [Pg.220]

Table 7 summarizes selected phase Eli studies of paclitaxel/radiation in esophageal cancer. Although pathologic complete response rates have been encouraging, ranging from 11 41 %, these regimens have not been tested in a randomized fashion against the more standard cisplatin, 5-FU based therapies. [Pg.227]

Arnould L, Arveux P, Couturier J, et al (2007) Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 13 6404-6409... [Pg.185]

Hartley A, Ho KF, McConkey C, Geh JI (2005) Pathological complete response following pre-operative chemoradio-therapy in rectal cancer analysis of phase II/III trials. Br J Radiol 78 934-938... [Pg.187]

Reitsamer R, Peintinger F, Prokop E, Hitzl W (2005) Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 16 867 870... [Pg.188]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...